XORTX Therapeutics Analyst Price Targets

XORTX Therapeutics Inc

XRTXNASDAQ

Trade with Public

$0.9900

-0.02-1.98%

마지막 업데이트: Oct 20, 9:49 AM

$1.04

0.032.97%

개요 뉴스 실적 전망 이벤트목표가재무 심리 비교 주식 보고서

XORTX Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for XORTX Therapeutics (XRTX).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$70Upside to Avg. PT+6970.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 4, 2024	Alliance Global Partners	James Molloy	PT Raise	Buy	$9→$14

Analyst Ratings News

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Alliance Global Partners analyst James Molloy maintains XORTX Therapeutics (NASDAQ:XRTX) with a Buy and raises the price target from $9 to $14.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.

Benzinga Insights

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Alliance Global Partners analyst James Molloy initiates coverage on XORTX Therapeutics (NASDAQ:XRTX) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Benzinga

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

Benzinga

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

Benzinga

XORTX Therapeutics Inc

XORTX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

뉴스

파트너 / 기고자

벤징가 글로벌

XORTX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

People Also Watch

People Also Watch

XORTX Therapeutics Inc

XORTX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAlliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

PROAlliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

뉴스

파트너 / 기고자

벤징가 글로벌

XORTX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAlliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

PROAlliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

Analysts Comment on Xyratex Acquisition Bids, Shares Continue to Gain

Wells Fargo Comments on Xyratex on In-Line Demand with Storage Subsystem Expectations

UPDATE: Cantor Fitzgerald Reiterates Hold Rating, Lowers PT on Xyratex

People Also Watch

People Also Watch

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11

PRO
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

PRO
Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11